Fig. 1: AF1q is a universal marker of neuroblastoma.
From: AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis
A AF1Q expression in cancer cell lines represented in the Broad Institute Cancer Cell Line Expression (CCLE) Expression resource. Cell lines by cell/tissue of origin followed by number of cell lines per category in parenthesis. Chronic lymphocytic leukemia (CLL); Acute myelocytic leukemia (AML); Diffuse large B cell lymphoma (DLBC lymphoma); Lung, non-small cell (Lung, NSC). B Boxplot representations of data from DepMap project (DepMap_Public_21Q4 release) for DEMETER2 dependency score of cell lines from various cancer types. The DEMETER2 score is based on data from a cell depletion assay. A lower DEMETER2 score indicates a higher likelihood that the gene of interest is essential in a given cell line. A score of 0 indicates a gene is not essential; correspondingly -1 is comparable to the median of all pan-essential genes. Neuroblastoma cell lines (n = 9) have the lowest DEMETER2 score with enriched p-value < 7.4e-07 (significance obtained from DepMap_Public_21Q4). C Gene expression levels of MYCN, NTRK1 and AF1Q in microarrays from two large datasets of human neuroblastoma tumor transcriptomes, represented as z-scores. Results show the relative gene expression in high-risk MYCN amplified (HRA, gray bars), high-risk MYCN non-amplified (HRN, black bars) and low-risk (LR, white bars) tumors. For TARGET HuEx dataset, total tumor number = 249; for HRA, HRN and LR, n = 68, 151 and 30, respectively; for MAQCII Agilent dataset, total tumor number = 416; for HRA, HRN and LR, n = 69, 71 and 281, respectively.
